Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ (tofacitinib citrate) Labeling to Include Additional Patient-Reported Out

19-11-2013 Business Wire HealthComments (0)

PfizerPharmaceuticalXeljanz

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate) to include additional Patient-Reported Outcomes (PRO) data in the label. These additional data show improvement in patients receiving XELJANZ based on health-related outcome measures reported by patients, including vitality, role emotional, physical function, bodily pain, social function,

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top